EMA Lapsed: Temybric Ellipta (fluticasone furoate;umeclidinium bromide;vilanterol trifenatate) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

The EMA lists Temybric Ellipta as lapsed in the European market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Temybric Ellipta (fluticasone furoate; umeclidinium bromide; vilanterol trifenatate)

Snippet

Status: Lapsed. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 11/12/2021